Phase I Clinical Trial Results of Auranofin, a Novel Antiparasitic Agent

• Published in: Antimicrobial agents and chemotherapy Vol. 61; no. 1
• Main Authors: Capparelli, Edmund V, Bricker-Ford, Robin, Rogers, M John, McKerrow, James H, Reed, Sharon L
• Format: Journal Article
• Language: English
• Published: United States American Society for Microbiology 01.01.2017
• Subjects: Administration, Oral; Adult; Antiparasitic Agents; Antiparasitic Agents - blood; Antiparasitic Agents - pharmacokinetics; Antirheumatic Agents; Antirheumatic Agents - blood; Antirheumatic Agents - pharmacokinetics; Auranofin; Auranofin - blood; Auranofin - pharmacokinetics; Computer Simulation; Drug Administration Schedule; Drug Dosage Calculations; Drug Repositioning; Entamoeba histolytica; Entamoeba histolytica - drug effects; Entamoeba histolytica - growth & development; Experimental Therapeutics; Female; Giardia; Giardia intestinalis; Giardia lamblia; Giardia lamblia - drug effects; Giardia lamblia - growth & development; Gold - blood; Half-Life; Healthy Volunteers; High-Throughput Screening Assays; Humans; Inhibitory Concentration 50; Male; Metronidazole - pharmacology; Models, Statistical; Tissue Distribution; antiparasitic agents; auranofin; phase I trial

Under an NIH priority to identify new drugs to treat class B parasitic agents, we performed high-throughput screens, which identified the activity of auranofin (Ridaura) against Entamoeba histolytica and Giardia intestinalis, major causes of water- and foodborne outbreaks. Auranofin, an orally admin...